Roche Holding AGRO.SW
What Roche Holding AG does.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | CHF 65.8B | CHF 60.4B | CHF 62.4B | CHF 63.4B |
| Net income | CHF 12.4B | CHF 11.5B | CHF 8.3B | CHF 12.9B |
| Free cash flow | CHF 13.3B | CHF 11.4B | CHF 15.1B | CHF 13.1B |
More on RO.SW.
- Roche Holding AG summary
- Roche Holding AG financial statements
- Roche Holding AG key metrics
- Roche Holding AG health scores
- Roche Holding AG valuation
- Roche Holding AG dividends
- Roche Holding AG peers
- Roche Holding AG annual reports
Figures from Roche Holding AG's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.